From shield to sword: countervailing and anti-dumping duties as protectionist weapons
Cambridge International Law Journal · 01.06.2026 · 15 (1) · 99-122
DOI: 10.4337/cilj.2026.01.05 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cambridge International Law Journal, erschienen am 01.06.2026. Verfasst von Antoine Comont. Die Arbeit nennt 143 Literaturangaben.
Abstract (Originalsprache)
This article examines how anti-dumping and countervailing measures, originally designed as trade remedies to ensure a fair level playing field, have been progressively ‘weaponised’ in the pursuit of protectionist strategies. First, it analyses the procedural architecture of the Anti-Dumping Agreement and the Subsidies and Countervailing Measures Agreement, showing how their ambiguities surrounding some legal concepts and some requirements allow Members to turn trade remedies into a protectionist weapon in support of their industrial policy. Second, it highlights the geopolitical and distributive effects of this regime, demonstrating that trade remedies are disproportionately initiated by economically powerful Members and largely directed against developing and least developed countries, particularly in sectors at the heart of global value chains. Third, the article explores four approaches for ‘de-weaponisation’ through political, normative and institutional reform.
Zitieren
APA
Comont, A. (2026). From shield to sword: countervailing and anti-dumping duties as protectionist weapons. Cambridge International Law Journal, 15(1), 99-122. https://doi.org/10.4337/cilj.2026.01.05
Vancouver
Comont A. From shield to sword: countervailing and anti-dumping duties as protectionist weapons. Cambridge International Law Journal. 2026;15(1):99-122. doi:10.4337/cilj.2026.01.05
BibTeX
@article{Comont2026,
author = {Comont, Antoine},
title = {From shield to sword: countervailing and anti-dumping duties as protectionist weapons},
journal = {Cambridge International Law Journal},
year = {2026},
volume = {15},
number = {1},
pages = {99--122},
doi = {10.4337/cilj.2026.01.05}
}
EUVIMED